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Abstract 
FANCB protein is a component of the Fanconi 
Anemia (FA) core complex needed for DNA repair. 
Within the core complex, FANCB forms a protein 
subcomplex with two other proteins, FAAP100, and 
an E3 RING ligase FANCL (BL100) to 
monoubiquitinate FANCD2 and FANCI (ID2), a 
process that is defective in 95% of all FA patients. 
FA is a rare, genetic cancer pre-disposition 
syndrome characterized by chromosomal instability 
and hypersensitivity to DNA crosslinking agents, 
such as those used in chemotherapy like mitomycin 
C (MMC) (Kennedy  D'Andrea, 2006). FANCB is 
the only known X-linked FA gene, and mutations 
account for 1% of FA cases (Alter  Rosenberg, 
2013). 
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Identity 
Other names: FAB, FA2, FACB 
HGNC (Hugo): FANCB 
Location : Xp22.2 
Location (base pair) 
FANCB is located on the X chromosome between 
base pairs 14,690,863 to 14,873,255 at position 
Xp22.2 on the short arm (p) of the X chromosome. 
DNA/RNA 
Description 
FANCB has 10 exons, and the translation start site is 
in exon 3 (Meetei et al., 2004). 
Transcription 
The FANCB gene undergoes X-inactivation.  
The mutated FANCB allele is preferentially 
inactivated in female carriers (so the wild-type allele 
is expressed), while males with mutations in FANCB 
get FA (Meetei et al., 2004).  
FANCB linked FA accounts for 1% of FA cases, and 
only affects male patients. 
Figure 1:  Genomic context of FANCB on chromosome (Adapted from NCBI). 
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Figure 2:  Schematic of FANCB gene. Black represents exons (protein coding regions), white represents introns (non-coding). 
Adapted from McCauley et al. 2011. 
 
 
Protein 
Description 
The FANCB gene encodes FANCB protein 
comprised of 859 amino acids, with a molecular 
mass of 97726 Da. It has a putative C-terminal 
nuclear localization signal (Meetei et al., 2004). 
 
Figure 3: The 9 protein core complex associates in 3 
distinct subcomplexes: AG20 (FANC A, G, FAAP20), 
BL100 (FANC B, L, FAAP100), and CEF (FANC C,E,F). 
Dashed lines indicate groupings of sub-complexes, while 
triple lines indicate putative direct protein interactions. 
Expression 
Low expression in tissues. Results from Illumina 
bodyMap2 transcriptome (BioProject: PRJEB2445) 
of high throughput sequencing of individual and 
mixture of 16 human tissue RNA showed highest 
expression in white blood cells (mean RPKM 0.32), 
testes (mean RPKM 0.23), brain (mean RPKM 
0.168), adrenal (mean RPKM 0.164), ovary (mean 
RPKM 0.153), and lymph nodes (mean PRKM 
0.149). Another RNA sequencing project of total 
RNA from 20 human tissues (BioProject: 
PRJNA280600) found highest FANCB expression 
in brain cerebellum (mean RPKM 0.789), and 
thymus (mean RPKM 0.524).  
BioProject PRJEB4337 performed HPA RNA 
sequencing of normal tissues found highest FANCB 
expression in bone marrow and in lymph nodes.  
BioProject PRJNA270632 looked at tissue specific 
FANCB RNA induction during human fetal 
development from 6 tissues between 10-20 weeks 
gestational time. 
Function 
FANCB is a component of the Fanconi Anemia 9 
protein "core complex" that acts as a multiunit 
ubiquitin ligase to ubiquitinate FANCD2 and 
FANCI in response to DNA damage incurred during 
DNA replication in S-phase, or to detection of 
interstand cross links (ICL) (Ceccaldi, Sarangi,  
D'Andrea, 2016).  
The key event in the FA pathway is the 
monoubiquitination of ID2 that activates 
downstream DNA repair proteins.  
The core complex is comprised of 3 separate sub-
complexes, , FANCG, FAAP20 (AG20), FANCC, 
FANCE, FANCF (CEF), and FANCB, FANCL, 
FAAP100 (BL100) (Huang et al., 2014; Medhurst et 
al., 2006). The BL100 sub-complex is critical to core 
complex assembly as it forms a bridge between 
AG20 and CEF (van Twest et al., 2017). The BL100 
subcomplex is dimeric, and FANCB homodimer 
forms the interface between two copies of FANCL 
(a RING E3 ligase), and FAAP100 to simultaneously 
ubiquitinate FANCD2 and FANCI (ID2) (Swuec et 
al., 2016; van Twest et al., 2017). Correspondingly, 
FANCB and FAAP100 stabilize FANCL (Rajendra 
et al., 2014), and enhance its activity by 5-fold in 
invitro assays (Ling et al., 2007). Mutation in any 
one of the 19 FA genes results in defective DNA 
repair. 
Mutations 
Somatic 
Somatic FANCB mutations are very rare, and may 
occur at normal mutagenesis rate. Small insertions, 
point mutations, and large deletions have been 
reported in the FANCB gene (McCauley et al., 2011; 
Meetei et al., 2004). Most FANCB mutations result 
in truncation of the encoded protein. 
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Figure 4:  Schematic of Fanconi Anemia DNA damage response pathway. In response to interstrand cross links (ICL), or DNA 
damage from DNA replication, FANCM recruits the 9 protein core complex to DNA damage sites to monoubiquitinate FANC D2 
and I. The core complex is comprised of 3 sub-complexes AG20 (FANC A, G, FAAP20), BL100 (FANC B, L, FAAP100), and 
CEF (FANC C,E,F).  Dashed lines indicate groupings of sub-complexes, while triple lines indicate putative direct protein 
interactions. Within the core complex, FANCL has a RING E3 domain with ubiquitin ligase activity, but mutation in any one of the 
FA genes leads to defective DNA repair. Ubiquitinated ID2 is activated, and localized to chromatin in nuclear foci to interact with 
downstream DNA repair proteins (FANCD1, PALB2 (FANCN)) to repair DNA via homologous recombination. Once DNA repair is 
completed, USP1 deubiquitinates ID2 so that DNA damage response can be reinitiated. Figure adapted from 
https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/fancb. 
 
  
Figure 5:  FANCB dimer coordinates FANCD2:FANCI 
monoubiquitination by two FANCL RING-ligases. 
 
Implicated in 
Fanconi Anemia 
Disease 
Mutated FANCB is implicated in Fanconi Anemia 
(FA), a rare genetic condition that results in 
progressive bone marrow failure (pancytopenia), 
congenital malformations in 75% of patients (short 
stature, urogenital defects, café au lait spots, skeletal 
malformations), and cancer pre-disposition 
(primarily acute myeloid leukaemia, and certain 
solid tumours) (Alter, 2014).  
As the only X-linked FA gene, FANCB accounts for 
1% of FA cases, in all other instances FA is 
autosomal recessive. Mutations in FANCB (and all 
other core complex FA proteins) is associated with 
hypersensitivity to DNA-damaging agents, 
chromosomal instability with increased 
chromosome breakage and defective DNA repair. In 
addition to FA, some patients with FANCB 
mutations also exhibit hydrocephalus-VACTERL 
(vertebral, anal, cardiac, tracheo-esophageal fistula, 
renal, and limb anomalies) syndrome. A frameshift 
FANCB mutation that results in a truncated protein 
(stop codon at position 446) was associated with 
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VACTERL-H (Holden et al., 2006; McCauley et al., 
2011).  
Prognosis  
The prognosis for FA is poor as there is no cure, and 
the average lifespan is 20-30 years.  
If no congenital abnormalities are apparent at birth, 
patients are often diagnosed with FA when they 
present with aplastic anemia ages 8-10 (>700 fold 
risk) (Alter, 2014).  
Bone marrow transplants are often conducted to 
correct the haematological issues associated with 
FA, however due to faulty DNA repair FA patients 
retain high cancer risk particularly leukaemia, and 
head and neck squamous cell carcinomas 
(approximately 500 fold risk) (Shimamura  Alter, 
2010).  
Diagnostic 
Diagnostics for FA is done with a chromosomal 
breakage test; when treated with interstand 
crosslinking agents such as mitomycin C (MMC) or 
diepoxybutane (DEB) FA cells exhibit high number 
chromosomal breakages, and abnormalities as 
compared to normal cells. 
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